Measuring Emphasys hip implant movement with radiostereometric analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multi-centre, non-randomized, non-controlled study that uses model-based radiostereometric analysis (RSA) to measure implant migration. The primary endpoints are mean superior cup migration of the Emphasys Shell and mean inferior stem migration of the Emphasys Stem over the first two years post-implantation. Data collected will be compared to historical Pinnacle Acetabular Shell results (DSJ_2018_02). Subjects receive standard primary total hip arthroplasty care using the protocol-specified products and return for scheduled RSA imaging and hip outcome questionnaires.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Individuals requiring primary THA for a severely painful and/or disabled joint from osteoarthritis, traumatic arthritis, rheumatoid arthritis, or congenital hip dysplasia, AVN of the femoral head or acute traumatic fracture of the femoral head or neck.
2. Individuals who are able to speak, read and comprehend the informed patient consent document and willing and able to provide informed patient consent for participation in the study and have authorized the transfer of his/her information to DePuy Synthes.
3. Individuals who are willing and able to return for follow-up as specified by the study protocol.
4. Individuals who are a minimum age of 21 years at the time of consent.
5. Individuals who are willing and able to complete the Subject Hip Outcomes questionnaires as specified by the study protocol.

Exclusion Criteria:

1. Individuals who have active local or systemic infection.
2. Individuals who have loss of musculature, neuromuscular compromise or vascular compromise that would impact rehabilitation following surgery.
3. Individuals with poor bone quality, such as osteoporosis, where in the surgeon's opinion, there could be considerable migration of the prosthesis or require additional acetabular cup fixation using screws, or a significant chance of fracture of the femoral shaft and/or the lack of adequate bone to support the implant(s).
4. Individuals with Charcot's or Paget's disease.
5. Individuals who, in the judgement of the investigator, would not be a candidate for protocol allowable components to be used for their THA.
6. Women who are pregnant or lactating.
7. Individuals who have had a contralateral hip that was implanted less than 6 months prior to the time of consent into this study or individuals that expect to have a contralateral hip implanted in the following 6 months at the time of consent into this study.
8. Individuals that have amputations in either leg that would impact rehabilitation following surgery.
9. Individuals who are bedridden
10. Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
11. Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
12. Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have a psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
13. Individuals diagnosed and taking prescription medications to treat a muscular disorder that limits mobility due to sever stiffness and pain such as fibromyalgia or polymyalgia.
14. Subject has a medical condition with less than 2 years life expectancy.
15. Individual has a BMI \>45 kg/m2.

Where it's running

• Orthopaedic Innovation Centre
  Winnipeg, Manitoba, Canada Recruiting

Study contacts

• Principal investigator: Thomas Turgeon, MD — Concordia Hospital
• Study coordinator: Sarah Tran
• Email: stran@orthoinno.com
• Phone: 204-926-1231

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ceramic hip resurfacing vs total hip arthroplasty for hip OA

  This trial tests whether ceramic hip resurfacing helps people with hip OA walk farther each day than a modern total hip replacement.

  Recruiting Danderyd Hospital · Danderyd · NCT07839403

• Dexmedetomidine during hip replacement to modulate nerves and inflammation

  A randomized, placebo-controlled study tests whether intravenous dexmedetomidine given during spinal anesthesia with a PENG nerve block can help regulate the body's stress and inflammatory response and improve recovery after hip replacement.

  Recruiting Poznan University of Medical Sciences · Poznan · NCT07743853

• Preoperative Fasting to Shape the Gut with Hip Replacement

  This trial tests whether a 20-day preoperative fasting plan can lower inflammatory signals and broaden gut microbes in adults undergoing total hip arthroplasty.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07651462

• Cryoneurolysis for Chronic Pain: 6- and 12-Month Outcomes in Routine Care

  This study tests whether cryoneurolysis, done as part of standard care for people with chronic pain, leads to meaningful improvements over 6 to 12 months.

  Recruiting Yale University · Old Saybrook, Connecticut · NCT07639060

• Spinal anesthesia with intrathecal morphine vs PENG block (with or without dexamethasone) for hip replacement

  In people aged 60 and older undergoing total hip arthroplasty, this study tests whether three anesthesia approaches provide better pain control and fewer side effects: spinal with intrathecal morphine, spinal with a PENG block, or spinal with a PENG block plus dexamethasone.

  Recruiting Poznan University of Medical Sciences · Poznan · NCT07584200

• Intravenous dexamethasone for better pain control after hip replacement with a PENG block

  This study tests whether giving dexamethasone through a vein, in 0, 4, or 8 mg doses, helps control pain after total hip arthroplasty when used with a PENG block.

  Recruiting Poznan University of Medical Sciences · Poznan · NCT07581470

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.